Next Article in Journal
Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma
Next Article in Special Issue
An Apoptotic and Endosymbiotic Explanation of the Warburg and the Inverse Warburg Hypotheses
Previous Article in Journal
Characterization of Apoptosis, Autophagy and Oxidative Stress in Pancreatic Islets Cells and Intestinal Epithelial Cells Isolated from Equine Metabolic Syndrome (EMS) Horses
Previous Article in Special Issue
Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
Open AccessArticle

Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells

Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland
Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestr. 1, 3012 Bern, Switzerland
Department of Visceral Surgery and Medicine, University Hospital Bern, 3010 Bern, Switzerland
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(10), 3069;
Received: 15 September 2018 / Revised: 4 October 2018 / Accepted: 4 October 2018 / Published: 8 October 2018
Esophageal adenocarcinoma (EAC) is a highly lethal cancer type with an overall poor survival rate. Twenty to thirty percent of EAC overexpress the human epidermal growth factor receptor 2 (Her2), a transmembrane receptor tyrosine kinase promoting cell growth and proliferation. Patients with Her2 overexpressing breast and gastroesophageal cancer may benefit from Her2 inhibitors. Therapy resistance, however, is well documented. Since autophagy, a lysosome-dependent catabolic process, is implicated in cancer resistance mechanisms, we tested whether autophagy modulation influences Her2 inhibitor sensitivity in EAC. Her2-positive OE19 EAC cells showed an induction in autophagic flux upon treatment with the small molecule Her2 inhibitor Lapatinib. Newly generated Lapatinib-resistant OE19 (OE19 LR) cells showed increased basal autophagic flux compared to parental OE19 (OE19 P) cells. Based on these results, we tested if combining Lapatinib with autophagy inhibitors might be beneficial. OE19 P showed significantly reduced cell viability upon double treatment, while OE19 LR were already sensitive to autophagy inhibition alone. Additionally, Her2 status and autophagy marker expression (LC3B and p62) were investigated in a treatment-naïve EAC patient cohort (n = 112) using immunohistochemistry. Here, no significant correlation between Her2 status and expression of LC3B and p62 was found. Our data show that resistance to Her2-directed therapy is associated with a higher basal autophagy level, which is not per se associated with Her2 status. Therefore, we propose that autophagy may contribute to acquired resistance to Her2-targeted therapy in EAC, and that combining Her2 and autophagy inhibition might be beneficial for EAC patients. View Full-Text
Keywords: autophagy; Her2; Lapatinib; LC3B; p62; OE19; Her2 inhibitor; resistance; esophageal adenocarcinoma autophagy; Her2; Lapatinib; LC3B; p62; OE19; Her2 inhibitor; resistance; esophageal adenocarcinoma
Show Figures

Graphical abstract

MDPI and ACS Style

Janser, F.A.; Adams, O.; Bütler, V.; Schläfli, A.M.; Dislich, B.; Seiler, C.A.; Kröll, D.; Langer, R.; Tschan, M.P. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. Int. J. Mol. Sci. 2018, 19, 3069.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop